A cluster randomized, placebo control trial to evaluate the efficacy of a spatial repellent (Mosquito ShieldTM) against Aedes-borne virus infection among children ≥ 4–16 years of age in the Gampaha District, Sri Lanka: study protocol (the AEGIS program)
Authors: Tissera Hasitha , Dheerasinghe D.S. Anoja F. , Malavige Neelika , de Silva H. Asita , Morrison Amy C. , Scott Thomas W. , Reiner Robert C. , Grieco John P. , Achee Nicole L. 
Published: December 2022

Abstract

Background: Spatial repellents (SRs) have been widely used for prevention of mosquito bites, but their efficacy in reducingAedes-borne viruses (ABV) has not been tested rigorously at large-scale in Asia. To address this knowledge gap, a trial to evaluate the efficacy of Mosquito Shield™, a transfluthrin SR, was developed in Gampaha District of Sri Lanka across three Medical Officer of Health areas; i.e., Negombo, Wattala, Kelaniya.Methods: This trial is a cluster-randomized, placebo-controlled, double-blinded clinical trial. A total of ~14,430 subjects aged ≥ 6 months in 30 clusters (15 intervention, 15 placebo) from ~3,900 households (HH) will be randomly selected for enrolment into a ‘febrile surveillance cohort.’ A subset of the surveillance cohort, ~3,570 subjects aged ≥4-16 years that test seronegative (naïve) or are serologically positive for a previous single dengue virus (DENV) infection (monotypic) at baseline sampling, will be enrolled into a ‘longitudinal cohort’ for measuring DENV infection based on laboratory-confirmed seroconversion during the trial. Persons identified positive for antibodies against multiple DENV serotypes (multi-typic) at baseline, will be monitored for secondary analyses. Active ABV disease will be assessed using an enhanced passive-surveillance system with case ascertainment performed in designated healthcare facilities. Serum samples will be taken from longitudinal cohort subjects within 1-2 weeks of when intervention is first deployed (T0) with additional samples taken ~12 (T1) and ~24 months (T2) from baseline sampling. DENV seroconversion and ABV active disease rates from baseline (pre-intervention) and follow-up (post-intervention) samples will be compared between intervention and placebo clusters. Participating houses will be monitored entomologically (indoor adultAe. aegyptipopulation densities and adult female blood-fed status) within 3 months before intervention deployment and monthly during the intervention phase. Entomological surveys will monitor indoor adultAe. aegyptipopulation densities and blood-fed status. Dengue incidence in each cohort will be estimated and compared to determine the public health benefit of using an SR. Entomological parameters will be measured to determine if there are entomological correlates of SR efficacy that may be useful for the evaluation of new SR products.Discussion: The trial will serve as an efficacy assessment of SR products in South Asia. Results will be submitted to the World Health Organization Vector Control Advisory Group for assessment of public health value towards an endorsement to recommend inclusion of SRs in ABV control programs. Trial registration: Sri Lanka Clinical Trial Registry SLCTR/2022/018. Registered July 1, 2022. https://slctr.lk/trials/slctr-2022-018 ClinicalTrials.gov NCT05452447. Registered July 11, 2022. https://clinicaltrials.gov/ct2/show/record/NCT05452447?cond=dengue&amp;cntry=LK&draw=2&rank=4 The Universal Trial Number is U1111-1275-3055.